<div id="readability-page-1" class="page"><div id="parent_top_div"><h3>  Market view by by Ajit Mishra, Religare Broking</h3> <p>Markets witnessed a strong rebound on Wednesday, extending gains after the recent consolidation phase, supported by favourable global cues. The Nifty opened gap-up and remained range-bound throughout the session and finally settled at the 24,231.30 level, up by 1.63 per cent. The rally was broad-based, with all major sectors trading in the green—led by IT, realty and energy. Broader markets outperformed once again, with midcap and smallcap advancing over 2 per cent, reflecting strong risk-on sentiment and improved market breadth. The up move was primarily driven by improving global sentiment amid renewed hopes of US–Iran negotiations, which led to a sharp cooling in crude oil prices below the $100 mark. This eased concerns around inflation and supported emerging market equities like India. Stability in the rupee and a decline in volatility (India VIX) also contributed to the positive undertone, while optimism around the ongoing earnings season kept sentiment buoyant.</p> <p>  From a technical perspective, the Nifty has again reclaimed the 24,000 mark, indicating strengthening momentum in the ongoing recovery phase. We are now eyeing the index to inch towards the 24,350–24,600 zone, while the major hurdle would be around 24,800, i.e. 200 DEMA, while the support has shifted higher to the 23,900–23,600 range. We thus reiterate our positive yet cautious stance with a focus on stock selection and overnight risk management. While the broader indices are showing noticeable outperformance in the recent rally, participants should stick only with the quality names.</p> <h3>  Stocks Recommendations</h3> <p><strong>Glenmark Pharmaceuticals | LTP: ₹2258.4| Recommendation: Buy | Target: ₹2410| Stop-loss: ₹2175</strong></p> <p>  Glenmark Pharmaceuticals has successfully retested the neckline of its broader triangular breakout and rebounded, signalling underlying strength in its price structure. The stock has sustained above this level, forming an elevated base through range-bound consolidation while holding above key moving averages.</p> <p>  Technically, it has established a buying pivot by breaking out of this base, indicating a continuation of the uptrend. Traders may consider accumulating the stock within the specified range. </p> <p><strong>State Bank of India | LTP: ₹1071.5| Recommendation: Buy | Target: ₹1140| Stop-loss: ₹1030</strong></p> <p>  We are seeing noticeable strength in the rate-sensitive pack, and SBI is trading in sync with the move. It has staged a recovery after the retest of its long-term moving average, i.e. 200 DEMA. It has also established a buying pivot near the medium-term moving average support zone while clearing the resistance zone around the 1,080 level. This indicates that the recovery could extend further and may lead to a resumption of the broader uptrend.</p> <p><strong>Tata Power Company | LTP: ₹421.85| Recommendation: Buy | Target: ₹450| Stop-loss: ₹406</strong></p> <p>Tata Power is exhibiting constructive bullish momentum, supported by a consistent formation of higher highs and higher lows. The price action is confined within an ascending channel and has surpassed a prior swing high, indicating improving sentiment and a potential trend continuation. Sustained trading above key moving averages, coupled with a recent surge in volume, reflects strengthening momentum and underlying demand. Participants may consider initiating long positions as per the given levels.<small> </small> <em><strong>(Disclaimer: This article is by Ajit Mishra, SVP – research, Religare Broking. Views expressed are his own.)</strong></em></p></div></div>

1678

<p>Nifty 指数强劲反弹，收于 24,231.30，上涨 1.63%，受到积极的全球市场信号和原油价格回落的支持。所有主要行业表现良好，尤其是信息技术、房地产和能源，中型股和小型股上涨超过 2%。分析师预计 Nifty 将目标指向 24,350–24,600，支撑位在 23,900–23,600。股票推荐包括购买 Glenmark Pharma、SBI 和 Tata Power，这些股票均显示出强劲的技术指标和进一步上涨的潜力</p>

Nifty eyes 24,600; SBI, Glenmark Pharma, Tata Power on analyst radar

Nifty 指数瞄准 24,600 点；SBI、Glenmark Pharma 和 Tata Power 受到分析师关注